Establishment Labs Announces Participation in the Cowen 41st Annual Healthcare Conference

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós and CFO Renee Gaeta will attend the Cowen 41st Annual Healthcare Conference from March 1-4, 2021. They are scheduled to present on March 2, 2021, at 9:50 am ET. A live webcast of their presentation will be available on the company's investor relations website, with an archived version accessible post-event. Establishment Labs focuses on women’s health, primarily in breast aesthetics and reconstruction, with products like Motiva Implants® available in over 80 countries.

Positive

• CEO and CFO participation in a major healthcare conference may enhance company visibility and investor interest.
• Motiva Implants® are available in over 80 countries, indicating strong global market reach.

Negative

• None.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Cowen 41^st Annual Healthcare Conference, which is being held March 1-4, 2021. Mr. Chacón-Quirós and Mrs. Gaeta are scheduled to speak to conference attendees at 9:50 am ET on Tuesday, March 2, 2021.

A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005105/en/

FAQ

When is Establishment Labs participating in the Cowen 41st Annual Healthcare Conference?

Establishment Labs will participate in the Cowen 41st Annual Healthcare Conference from March 1-4, 2021, with their presentation on March 2, 2021, at 9:50 am ET.

Who is speaking on behalf of Establishment Labs at the Cowen Conference?

CEO Juan José Chacón-Quirós and CFO Renee Gaeta will speak on behalf of Establishment Labs at the Cowen Conference.

Where can I watch the webcast of Establishment Labs' conference presentation?

The webcast can be viewed on the Establishment Labs investor relations website and will be archived there after the event.

What products does Establishment Labs offer?

Establishment Labs offers products including the Motiva Implants® and the Divina® 3D Simulation System, focusing on women's health.

In how many countries are Motiva Implants® available?

Motiva Implants® are currently commercially available in over 80 countries.